These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

307 related articles for article (PubMed ID: 21358672)

  • 21. Tat-binding protein-1, a component of the 26S proteasome, contributes to the E3 ubiquitin ligase function of the von Hippel-Lindau protein.
    Corn PG; McDonald ER; Herman JG; El-Deiry WS
    Nat Genet; 2003 Nov; 35(3):229-37. PubMed ID: 14556007
    [TBL] [Abstract][Full Text] [Related]  

  • 22. The positive regulation of p53 by the tumor suppressor VHL.
    Roe JS; Youn HD
    Cell Cycle; 2006 Sep; 5(18):2054-6. PubMed ID: 16969113
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Hypoxia and cell cycle regulation of the von Hippel-Lindau tumor suppressor.
    Liu W; Xin H; Eckert DT; Brown JA; Gnarra JR
    Oncogene; 2011 Jan; 30(1):21-31. PubMed ID: 20802534
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Regulation of E2F1 by the von Hippel-Lindau tumour suppressor protein predicts survival in renal cell cancer patients.
    Mans DA; Vermaat JS; Weijts BG; van Rooijen E; van Reeuwijk J; Boldt K; Daenen LG; van der Groep P; Rowland BD; Jans JJ; Roepman R; Voest EE; van Diest PJ; Verhaar MC; de Bruin A; Giles RH
    J Pathol; 2013 Sep; 231(1):117-29. PubMed ID: 23744542
    [TBL] [Abstract][Full Text] [Related]  

  • 25. The von Hippel-Lindau tumor suppressor gene and kidney cancer.
    Kaelin WG
    Clin Cancer Res; 2004 Sep; 10(18 Pt 2):6290S-5S. PubMed ID: 15448019
    [TBL] [Abstract][Full Text] [Related]  

  • 26. von Hippel-Lindau tumor suppressor protein stimulation by thrombin involves RhoA activation.
    Turcotte S; Desrosiers RR; Brand G; Béliveau R
    Int J Cancer; 2004 Dec; 112(5):777-86. PubMed ID: 15386385
    [TBL] [Abstract][Full Text] [Related]  

  • 27. The multifaceted von Hippel-Lindau tumour suppressor protein.
    Robinson CM; Ohh M
    FEBS Lett; 2014 Aug; 588(16):2704-11. PubMed ID: 24583008
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Von Hippel-Lindau tumor suppressor protein and hypoxia-inducible factor in kidney cancer.
    Maynard MA; Ohh M
    Am J Nephrol; 2004; 24(1):1-13. PubMed ID: 14654728
    [TBL] [Abstract][Full Text] [Related]  

  • 29. p53 stabilization and transactivation by a von Hippel-Lindau protein.
    Roe JS; Kim H; Lee SM; Kim ST; Cho EJ; Youn HD
    Mol Cell; 2006 May; 22(3):395-405. PubMed ID: 16678111
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Inhibition of hypoxia-inducible factor is sufficient for growth suppression of VHL-/- tumors.
    Zimmer M; Doucette D; Siddiqui N; Iliopoulos O
    Mol Cancer Res; 2004 Feb; 2(2):89-95. PubMed ID: 14985465
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Phosphorylation of von Hippel-Lindau protein by checkpoint kinase 2 regulates p53 transactivation.
    Roe JS; Kim HR; Hwang IY; Ha NC; Kim ST; Cho EJ; Youn HD
    Cell Cycle; 2011 Nov; 10(22):3920-8. PubMed ID: 22071692
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Role of the VHL (von Hippel-Lindau) gene in renal cancer: a multifunctional tumour suppressor.
    Nyhan MJ; O'Sullivan GC; McKenna SL
    Biochem Soc Trans; 2008 Jun; 36(Pt 3):472-8. PubMed ID: 18481984
    [TBL] [Abstract][Full Text] [Related]  

  • 33. NF-kappaB-dependent plasticity of the epithelial to mesenchymal transition induced by Von Hippel-Lindau inactivation in renal cell carcinomas.
    Pantuck AJ; An J; Liu H; Rettig MB
    Cancer Res; 2010 Jan; 70(2):752-61. PubMed ID: 20068166
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Clusterin is a secreted marker for a hypoxia-inducible factor-independent function of the von Hippel-Lindau tumor suppressor protein.
    Nakamura E; Abreu-e-Lima P; Awakura Y; Inoue T; Kamoto T; Ogawa O; Kotani H; Manabe T; Zhang GJ; Kondo K; Nosé V; Kaelin WG
    Am J Pathol; 2006 Feb; 168(2):574-84. PubMed ID: 16436671
    [TBL] [Abstract][Full Text] [Related]  

  • 35. In vitro and in vivo models analyzing von Hippel-Lindau disease-specific mutations.
    Rathmell WK; Hickey MM; Bezman NA; Chmielecki CA; Carraway NC; Simon MC
    Cancer Res; 2004 Dec; 64(23):8595-603. PubMed ID: 15574766
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Induction of the Mdm2 gene and protein by kinase signaling pathways is repressed by the pVHL tumor suppressor.
    Mabry AR; Singh A; Mulrooney B; Gorman J; Thielbar AR; Wolf ER; Mayo LD
    Proc Natl Acad Sci U S A; 2024 Jul; 121(31):e2400935121. PubMed ID: 39047034
    [TBL] [Abstract][Full Text] [Related]  

  • 37. VHL-mediated hypoxia regulation of cyclin D1 in renal carcinoma cells.
    Bindra RS; Vasselli JR; Stearman R; Linehan WM; Klausner RD
    Cancer Res; 2002 Jun; 62(11):3014-9. PubMed ID: 12036906
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Arginine refolds, stabilizes, and restores function of mutant pVHL proteins in animal model of the VHL cancer syndrome.
    Shmueli MD; Levy-Kanfo L; Haj E; Schoenfeld AR; Gazit E; Segal D
    Oncogene; 2019 Feb; 38(7):1038-1049. PubMed ID: 30194449
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Von hippel-lindau: a tumor suppressor links microtubules to ciliogenesis and cancer development.
    Kuehn EW; Walz G; Benzing T
    Cancer Res; 2007 May; 67(10):4537-40. PubMed ID: 17510376
    [TBL] [Abstract][Full Text] [Related]  

  • 40. pVHL mediates K63-linked ubiquitination of nCLU.
    Xue J; Lv DD; Jiao S; Zhao W; Li X; Sun H; Yan B; Fan L; Hu RG; Fang J
    PLoS One; 2012; 7(4):e35848. PubMed ID: 22532874
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 16.